Needham analyst David Saxon assigned a Hold rating to Irhythm Technologies (IRTC) today. The company’s shares closed last Monday at $188.01.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of 34.9% and a 100.0% success rate. Saxon covers the Healthcare sector, focusing on stocks such as BioTelemetry, LivaNova, and SI-Bone.
Currently, the analyst consensus on Irhythm Technologies is a Moderate Buy with an average price target of $231.00, implying a 21.9% upside from current levels. In a report issued on December 2, Oppenheimer also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
Based on Irhythm Technologies’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $71.94 million and GAAP net loss of $4.68 million. In comparison, last year the company earned revenue of $54.67 million and had a GAAP net loss of $18.29 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
iRhythm Technologies, Inc. is a commercial-stage digital healthcare company, which engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers ZIO which diagnose many arrhythmias, avoiding multiple indeterminate tests, allowing for appropriate medical intervention, and prevents serious downstream medical events. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
